Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors
- PMID: 19121409
- DOI: 10.1016/j.drudis.2008.12.002
Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors
Abstract
Protein kinases continue to hold tremendous promise for therapeutic intervention, and the search for novel, safe and efficacious kinase inhibitors has intensified over the past decade. Given that most kinases are readily inhibited by organic small molecules and that a wealth of structural data exists on kinase-inhibitor complexes, there has been almost universal success in the design and identification of potent kinase inhibitors. The issues of non-selectivity and congested IP space, however, present formidable challenges for the successful clinical development of these compounds. We describe a systematic approach implemented at Abbott to enable the rapid discovery and design of novel and potent kinase inhibitors that provide additional opportunities for targeting new intellectual property space and achieving acceptable selectivity profiles.
Similar articles
-
The role of structure in kinase-targeted inhibitor design.Curr Opin Drug Discov Devel. 2004 Jul;7(4):428-36. Curr Opin Drug Discov Devel. 2004. PMID: 15338952 Review.
-
Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases.Drug Discov Today. 2008 Jun;13(11-12):522-9. doi: 10.1016/j.drudis.2008.03.023. Epub 2008 May 5. Drug Discov Today. 2008. PMID: 18549979 Review.
-
High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.J Mol Biol. 2005 Oct 7;352(5):1134-56. doi: 10.1016/j.jmb.2005.07.074. J Mol Biol. 2005. PMID: 16139843
-
[Progress in the design of selective ATP-competitive kinase inhibitors].Yao Xue Xue Bao. 2007 Dec;42(12):1232-6. Yao Xue Xue Bao. 2007. PMID: 18338633 Review. Chinese.
-
Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.J Med Chem. 2009 Oct 22;52(20):6456-66. doi: 10.1021/jm901147e. J Med Chem. 2009. PMID: 19791746
Cited by
-
Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.Cell Commun Signal. 2020 Oct 21;18(1):164. doi: 10.1186/s12964-020-00600-2. Cell Commun Signal. 2020. PMID: 33087151 Free PMC article.
-
S6K2: The Neglected S6 Kinase Family Member.Front Oncol. 2013 Jul 24;3:191. doi: 10.3389/fonc.2013.00191. eCollection 2013. Front Oncol. 2013. PMID: 23898460 Free PMC article.
-
Progress in structure based drug design for G protein-coupled receptors.J Med Chem. 2011 Jul 14;54(13):4283-311. doi: 10.1021/jm200371q. Epub 2011 Jun 15. J Med Chem. 2011. PMID: 21615150 Free PMC article. Review. No abstract available.
-
Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery.ACS Med Chem Lett. 2010 Jul 22;1(8):439-42. doi: 10.1021/ml100136n. eCollection 2010 Nov 11. ACS Med Chem Lett. 2010. PMID: 24900229 Free PMC article.
-
Targeting the cancer kinome through polypharmacology.Nat Rev Cancer. 2010 Feb;10(2):130-7. doi: 10.1038/nrc2787. Nat Rev Cancer. 2010. PMID: 20094047 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous